

## Agenda

### Welcome and Overview

- **Ammar Qadan, Vice President Global Market Access, Illumina**

### Track I - The Current Landscape of Genetic Testing

- **Overview of the Genetic Testing Landscape and NGS Coverage Trends, 2020:** Trisha Brown, MS, CGC Director, Payer Partnerships and Ashley Arthur, Associate Director, Market Access-Illumina
- **Demystifying PLA Codes:** Lee Hilborne, MD, Professor of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Medical Director, Quest Diagnostics, and Deputy Director for Global Health, RAND Corporation
- **An Actuary View of Genetic Testing:** Bruce Pyenson, FSA, MAAA Principal, Consulting Actuary and Samantha Tomicki, MPH Healthcare Analytics Consultant -Milliman

### Track II - How to Evaluate Genetic Tests for Coverage

- **What Payers Should Know from the Evidence Framework Virtual Summit:** Deepti Babu, MS, CGC Founder, Integrity Content Consulting
- **Test Evaluation Frameworks:** James Almas, MD Vice President and National Medical Director of Clinical Effectiveness at LabCorp
- **Clinical utility and Technical Assessments - Lessons learned from Medicare and Abroad:** Kristine Bordenave, MD KKBordenave Consulting
- **Economic Utility & Aligning the Financial Incentives:** Lena Chaihorsky, Co-founder and Vice President, Payer Innovation, Alva10
- **Navigating the Genetic Testing Waters - Guidelines for Health Plan Medical Directors:** Thomas Rothfeld, MD Medical Director Optum
- **Beyond Utilization Management - New Ways to Gain Clarity Between Payers and Labs:** Rob Metcalf, CEO and Gillian Hooker, MS, CGC- Vice President-Concert Genetics

Track I and II Live Q&A: December 15<sup>th</sup> 12:00-1:30pm PT <https://bluejeans.com/583831269/>

### Track III - Leading Edge Genomics for Payers

- **Polygenic Risk Scores:** Jill Hagenkord, MD Chief Medical Officer, Optum Genomics
- **Liquid Biopsy:** Mark Hiatt, MD, Vice President Guardant Health
- **Measuring Tumor Mutational Burden (TMB) using Comprehensive Genomic Profiling to Predict Immunotherapy Response:** Phil Febbo, MD, Chief Medical Officer, Illumina
- **Whole Genome Sequencing - What's on the Report?:** Jeanette McCarthy, MPH, PhD, Senior Director Scientific Programs Fabric Genomics
- **Implementation of Clinical Utility of Rapid Whole Genome Sequencing as Demonstrated by a State-Funded Quality Improvement Project in Neonatal and Pediatric Intensive Care Units:** Lucia Guidugli, MD, PhD, FACMG, CGMBBS Associate Laboratory Director at the Rady Children's Institute of Genomic Medicine (RCIGM)

Track III Live Q&A: December 17<sup>th</sup> 10:00-11:30am PT <https://bluejeans.com/583831269/>

#### Track IV - Aligning with Labs-Organized by the Association of Molecular Pathology (AMP)

- **The Impact of Prior Authorization and Lab Benefit Managers on Labs:** Lloyd Hutchinson, PhD FABCC Associate Professor, University of Massachusetts Medical School
- **Next Generation Sequencing 101:** Salvatore Priore MD, PhD Assistant Professor of Clinical Pathology and Laboratory Medicine& Tanner Hagelstrom, PhD, MBA, FACMG Laboratory Director, Illumina Clinical Services Laboratory
- **Professional Interpretation of Next Generation Sequencing:** Samuel Caughron, MD FCAP President & CEO, MAWD Pathology Group and Eric Vail, MD Director, Molecular Pathology& Assistant Professor, Pathology and Laboratory Medicine, Cedars Sinai Medical Center
- **How Labs Ensure Quality:** Susan Hsiao, Assistant Professor at Columbia University Medical Center and Victoria Pratt, Director, Pharmacogenomics and Molecular Genetics Laboratories at Indiana University School of Medicine

Track IV Live Q&A: December 18<sup>th</sup> 10:00-11:30am PT <https://bluejeans.com/583831269/>